ZNF266 Inhibitors
Chemical inhibitors of ZNF266 function by interfering with various signaling pathways and enzymatic activities that ZNF266 is involved in. PD168393 acts by covalently binding to the ATP binding site of EGFR tyrosine kinase, thus irreversibly inhibiting its activity. This inhibition disrupts downstream signaling pathways that ZNF266 may be a part of, resulting in a decrease in ZNF266's functional role. Similarly, PP2, a Src family kinase inhibitor, prevents the phosphorylation of substrates that could interact with ZNF266, leading to an inhibition of its functionality. LY294002, a PI3K inhibitor, blocks the PI3K/AKT signaling pathway, which in turn can affect the activity of ZNF266 if it is involved in this pathway. Inhibition of PI3K leads to reduced activation of AKT, thereby inhibiting ZNF266's function in this signaling cascade.
Further addressing the modulation of ZNF266 activity, PD98059 and U0126 specifically inhibit MEK1/2, which are crucial regulators of the ERK pathway. The inhibition of MEK1/2 by these chemicals results in decreased ERK phosphorylation and activity, which can reduce ZNF266's role if it is regulated by the ERK pathway. SP600125 targets JNK, another kinase that could be relevant to ZNF266 function, and its inhibition can consequently suppress the functional role of ZNF266 within the JNK pathway. SB203580, a p38 MAP kinase inhibitor, disrupts stress response pathways and can inhibit ZNF266 if it is engaged in these pathways. Likewise, Y-27632, which inhibits the Rho/ROCK pathway, can suppress ZNF266's function related to cytoskeletal organization. PD173074 and SU5402, both selective FGFR inhibitors, block FGFR tyrosine kinase activity and can inhibit ZNF266 if it functions within FGFR signaling pathways. Lastly, Chelerythrine, a potent inhibitor of PKC, can suppress ZNF266's activity within PKC-related signaling pathways, and Dasatinib, a broad-spectrum tyrosine kinase inhibitor, can inhibit ZNF266 by targeting kinases that regulate signaling pathways in which ZNF266 is involved.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs) which are involved in cell cycle regulation. As ZNF28 can be regulated during different cell cycle phases, the inhibition of CDKs can lead to the functional inhibition of ZNF28. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is an inhibitor of c-Raf kinase. c-Raf is a part of the MAPK/ERK pathway, which may regulate the activity of ZNF28. Inhibiting c-Raf would disrupt this pathway and consequently inhibit the functional activity of ZNF28. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which works upstream in the MAPK/ERK pathway. By inhibiting MEK, PD98059 can disrupt the phosphorylation events that are critical for the functional activity of ZNF28 within this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in the regulation of transcription factors and could affect the activity of ZNF28 by inhibiting the phosphorylation states that ZNF28 may require for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. The PI3K/Akt pathway is crucial for many transcription factors and inhibiting PI3K could disrupt signaling necessary for the full activity of ZNF28. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is part of a pathway that can regulate protein synthesis and transcription factors. By inhibiting mTOR, Rapamycin can lead to functional inhibition of ZNF28 by affecting its regulation or stability. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. As p38 MAP kinase can influence transcription factor activity, inhibiting it with SB203580 can result in the functional inhibition of ZNF28 by disrupting its activity within this signaling pathway. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of inhibitor proteins (IκBs) thus inhibiting NF-κB pathway which might be necessary for the regulation or activity of ZNF28. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is another proteasome inhibitor which similarly to MG132, can disrupt cellular signaling pathways such as NF-κB, and could lead to the functional inhibition of ZNF28 through these pathways. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
Mitoxantrone is a topoisomerase II inhibitor, which can affect DNA repair and replication processes. The inhibition of these processes can lead to the functional inhibition of ZNF28 by impairing its potential DNA-binding activity. | ||||||